Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/15975
Title: Metabolic phenotype by NMR spectroscopy: A biomarker for lung cancer
Authors: LOUIS, Evelyne 
BAETEN, Kurt 
Vandeurzen, Kurt
VANHOVE, Karolien 
Darquennes, Karen
MESOTTEN, Liesbet 
THOMEER, Michiel 
DE JONGE, Eric 
VAN DER SPEETEN, Kurt 
MEBIS, Jeroen 
ADRIAENSENS, Peter 
Issue Date: 2012
Source: Knowledge for Growth, Gent - Belgium, 24 May 2012
Abstract: Lung cancer is the second most common cancer in men and the third in women. Moreover, lung cancer is the leading cause of cancer death. In 2008, approximately 951.000 men and 427.000 women died from lung cancer worldwide. However, screening for lung cancer remains a challenge. Consequently, lung cancer is often diagnosed at a metastatic stage. New screening tools that would allow the detection of lung cancer at an early stage could possibly lead to a reduction in the mortality rate of this cancer. In this perspective, recent studies indicate that the determination of the metabolic profile of a blood sample by means of nuclear magnetic resonance spectroscopy has the potential for early disease detection. For several diseases, changes in metabolite concentrations have been shown to correlate with the presence of a certain disease. Identifying which changes in the metabolite concentrations correlate with the presence of lung cancer could allow us on the long-term to easily detect the presence of lung cancer in a simple blood sample. We hypothesize that metabolic phenotype analyses by NMR spectroscopy permit the detection of lung cancer and that the metabolic changes, detected in the blood of lung cancer patients, correlate with metabolic alterations at the tumor site. These metabolic changes in the tumor are measured by means of 18-fluorodeoxyglucose-positron emission tomography-computed tomography. Previous studies have shown that the uptake of 18F-FDG is substantially increased in most types of cancer, reflecting an elevated glucose consumption by tumor cells. Venous blood samples of 29 patients with confirmed lung cancer (before treatment or surgery) and 29 control subjects were collected. All patients had fasted for at least 6 hours and their blood glucose levels were lower than 200 mg/dl. To determine the correlation between metabolic changes in the blood and metabolic alterations at the tumor site, the patients in this study underwent a whole-body CT- and a PET-scan one hour after administration of 18F-FDG. The degree of tumoral 18F-FDG uptake was measured by the standardized uptake value, normalized for lean body mass (SUL). Application of supervised orthogonal partial least squares-discriminant analysis on a well-defined and selected panel of metabolites, allowed us to discriminate lung cancer patients from control subjects with a sensitivity of 93% and a specificity of 96%. These results are very promising, however, further validation with additional samples of lung cancer patients and controls is necessary. Furthermore, regression analysis between the SUL and all the metabolites present in the metabolic fingerprint will be performed to determine the correlation between the metabolic changes at the tumor site and changes in the blood.
Document URI: http://hdl.handle.net/1942/15975
Category: C2
Type: Conference Material
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Posterpresentatie Evelyne Louis.pptxPoster presentatie858.96 kBUnknownView/Open
Show full item record

Page view(s)

22
checked on May 27, 2022

Download(s)

6
checked on May 27, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.